TNFRSF8 and anaplastic large cell lymphoma: As expected, these cells maintained their ability to recognize and kill EBV+ tumors while, at the same time, targeting CD30+ cancer cells (such as HL and ALCL tumor cell lines) both in vitro and in vivo in a xenogeneic mouse model [23].